The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1

Journal of Human Virology

Volumn 4, Issue 1, 2001, Pages 1-7

  Su, J ^a   Andersson, E ^a   Horal, P ^a   Naghavi, M H ^a   Palm, A ^a   Wu, Y P ^a   Eriksson, K ^a   Jansson, M ^a   Wigzell, H ^a   Svennerholm, B ^a   Vahlne, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiretrovirals against HIV; Drug resistance; Glycyl prolyl glycine; HIV 1 laboratory strains; Short peptides; Street strains; Subtypes

Indexed keywords

ANTIVIRUS AGENT; GLYCOPROTEIN GP 120; GLYCYLPROLYLGLYCINAMIDE; RITONAVIR; TRIPEPTIDE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS STRAIN;

AMIDES; ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; HIV ENVELOPE PROTEIN GP120; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; VIRUS REPLICATION; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035153490     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy
2. Protease inhibitors: A therapeutic breakthrough for the treatment of patients with human immunodeficiency virus
3. Anti-human immunodeficiency virus drug combination strategies
4. Highly active antiretroviral therapy (HAART) for the treatment of infection of human immunodeficiency virus type 1
5. Managing resistance to anti-HIV drugs: An important consideration for effective disease management
6. HIV treatment failure: Testing for HIV resistance in clinical practice
7. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
8. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
9. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART)
10. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection
11. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
12. A neutralizing epitope of human immunodeficiency virus type 1 has homologous amino acid sequences with the active site of inter-alpha-trypsin inhibitor
13. Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120
14. - cells by two distinct mechanisms
15. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T cell leukemia viruses type I and type II using synthetic peptides
16. Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T cell recognition
17. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
18. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates
19. Expression, purification, and crystallization of the HIV-1 reverse transcriptase (RT)
20. Carrier bound templates for single tube reverse transcriptase assays and for combined purification and activity analyses, with special reference to HIV
21. Multiplicity activation of herpes simplex virus in mouse neuroblastoma (C1300) cells